Abstract
Purpose
Adjuvant chemotherapy (AC) is frequently considered in patients with high-risk stage II colorectal cancer (CRC). Among patients with stage II CRC who do not receive AC because they are not considered to be at high risk, 20–25% will develop recurrence and die from the disease. Elevated levels of KPNA2 have been observed in various cancers, and overexpression of KPNA2 is related to CRC progression.
Methods
We examined the expression of KPNA2 using 293 CRC tissues, including 118 with stage II CRC, and investigated the applicability of KPNA2 as a biomarker to predict high-risk stage II CRC. Moreover, we further investigated the role of KPNA2 as an oncogene in CRC carcinogenesis using in vitro functional studies.
Results
High KPNA2 expression was associated with vascular (p = 0.027) and lymphatic invasion (p = 0.009) in patients with stage II CRC. On multivariate analysis, high KPNA2 expression (HR 3.174, 95% CI 2.060–4.889; p < 0.001) was independently associated with survival in patients with CRC. The overall survival rate in patients with high KPNA2 expression was higher than that in patients with low KPNA2 expression in CRC (p < 0.001), even in patients with stage II CRC (p = 0.001). Additionally, KPNA2 was associated with tumorigenesis and cancer progression in CRC cells; high KPNA2 expression was associated with increased cell proliferation (p < 0.05), migration (p = 0.03), invasion (p = 0.001), and semisolid agar colony formation (p < 0.001).
Conclusion
KPNA2 expression is useful for identification of patients with high-risk stage II CRC who could benefit from AC and that KPNA2 may also be a promising therapeutic target.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. doi:10.1200/JCO.2008.20.6771
Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419
Dahl E, Kristiansen G, Gottlob K et al (2006) Molecular profiling of lasermicrodissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 12:3950–3960. doi:10.1158/1078-0432.CCR-05-2090
Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB (2010) A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 15:699–731. doi:10.1634/theoncologist.2010-0025
Goldfarb DS, Corbett AH, Mason DA, Harreman MT, Adam sa (2004) Importin alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol 14(9):505–514. doi:10.1016/j.tcb.2004.07.016
Gousias K, Becker AJ, Simon M, Niehusmann P (2012) Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas. J Neurooncol 109(3):545–553. doi:10.1007/s11060-012-0924-2
Jensen JB, Munksgaard PP, Sorensen CM et al (2011) High expression of karyopherin-alpha2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy. Eur Urol 59(5):841–848. doi:10.1016/j.eururo.2011.01.048
Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee KH (2015) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 47(2):127–141. doi:10.4143/crt.2017.118
Kau TR, Way JC, Silver PA (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4(2):106–117. doi:10.1038/nrc1274
Kelley JB, Talley AM, Spencer A, Gioeli D, Paschal BM (2010) Karyopherin alpha7 (KPNA7), a divergent member of the importin alpha family of nuclear import receptors. BMC Cell Biol 11:63. doi:10.1186/1471-2121-11-63
Lin J, Zhang L, Huang H et al (2015) MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. Oncotarget 6(27):23793–23806. doi:10.18632/oncotarget.4363
Merok MA, Ahlquist T, Røyrvik EC et al (2013) Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 24(5):1274–1282. doi:10.1093/annonc/mds614
Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358. doi:10.1056/NEJM199002083220602
National Comprehensive Cancer Network Guidelines (2013) http://nccn.org/professionals/physician_gls/fgui-delines.asp. Accessed 15 May 2013
NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB et al (2002) Cancer incidence in five continents, vol VII. IARC Scientific Publication, France, p 155
Poon IK, Jans DA (2005) Regulation of nuclear transport: central role in development and transformation? Traffic 6(3):173–186. doi:10.1111/j.1600-0854.2005.00268.x
Rachidi SM, Qin T, Sun S, Zheng WJL (2013) Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One 8(3):e57911. doi:10.1371/journal.pone.0057911
Sakai M, Sohda M, Miyazaki T et al (2010) Significance of karyopherin-{alpha} 2 (KPNA2) expression in esophageal squamous cell carcinoma. Anticancer Res 30(3):851–856
Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516. doi:10.1093/annonc/mds236
Sjo OH, Lunde OC, Nygaard K, Sandvik L, Nesbakken A (2008) Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis 10:33–40. doi:10.1111/j.1463-1318.2007.01302.x
Stewart M (2007) Molecular mechanism of the nuclear protein import cycle. Nat Rev Mol Cell Biol 8(3):195–208
Strambu V, Garofil D, Pop F, Radu P, Bratucu M, Popa F (2014) Translating clinical research of molecular biology into a personalized, multidisciplinary approach of colorectal cancer patients. J Med Life 7(1):17–26
van der Watt PJ, Maske CP, Hendricks DT et al (2009) The karyopherin proteins, Crm1 and karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124(8):1829–1840. doi:10.1002/ijc.24146
Vand Ogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558. doi:10.1126/science.1235122
Vatandoust S, Price TJ, Karapetis CS (2015) Colorectal cancer: metastases to a single organ. World J Gastroenterol 21(41):11767–11776. doi:10.3748/wjg.v21.i41.11767
Wang CI, Chien KY, Wang CL et al (2012) Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in non small cell lung cancer. Mol Cell Proteomics 11(11):1105–1122. doi:10.1074/mcp.M111.016592
Winnepenninckx V, Lazar V, Michiels S et al (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98(7):472–482. doi:10.1093/jnci/djj10
Yang MH, Chang SY, Chiou SH et al (2007) Overexpression of NBS1 induces epithelial–mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 26:1459–1467
Yoshitake K, Tanaka S, Mogushi K et al (2011) Importin-alpha1 as a novel prognostic target for hepatocellular carcinoma. Ann Surg Oncol 18(7):2093–2103. doi:10.1245/s10434-011-1569-7
Zhang Y, Zhang M, Yu F, Lu S, Sun H, Tang H, Peng Z (2015) Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer. J Exp Clin Cancer Res 34(1):145. doi:10.1186/s13046-015-0261-3
Zheng M, Tang L, Huang L, Ding H, Liao WT, Zeng MS, Wang HY (2010) Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 116(4):884–891. doi:10.1097/AOG.0b013e3181f104ce
Acknowledgements
We thank the colorectal cancer patients and their families. They generously donated valuable tissue samples.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2015R1D1A3A01016798) and the Soonchunhyang University Research Fund.
Conflict of interest
The authors made no disclosures.
Rights and permissions
About this article
Cite this article
Jeong, D., Kim, H., Ban, S. et al. Karyopherin α-2 is a reliable marker for identification of patients with high-risk stage II colorectal cancer. J Cancer Res Clin Oncol 143, 2493–2503 (2017). https://doi.org/10.1007/s00432-017-2512-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-017-2512-5